≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback

Retrobulbar neuritis in diseases classified elsewhere

DOID EFO Endpoint Browser PheWeb

H7_RETROBULBNEURINOTH

optic neuritis: Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain.The conditionmay cause sudden, reduced vision in the affected eye(s). While the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis , drug toxicity and deficiency of vitamin B-12. Vision often returns to normal within 2-3 weeks without treatment. In some cases, corticosteroids are given to speed recovery. If known, the underlying cause should be treated.

Suggest a new description

Endpoint definition

↥

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

2 out of 7 registries used, show all original rules.

133

4. Check minimum number of events

None

133

5. Include endpoints

None

133

6. Filter based on genotype QC (FinnGen only)

133

Control definitions (FinnGen only)

Control exclude
H7_OPTNERVE

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 604 436 164
Only index persons 579 422 157
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.00
Only index persons 0.01 0.02 0.01
Median age at first event (years)
Whole population 41.59 42.05 40.49
Only index persons 41.30 41.71 40.20

-FinnGen-

Key figures

All Female Male
Number of individuals 133 106 27
Unadjusted period prevalence (%) 0.03 0.04 0.01
Median age at first event (years) 39.89 39.34 42.05

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
117
Matched controls
1170
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G35
ICD-10 Finland
Multiple sclerosis
1514.6
126.9
102
5
109
Kela drug reimbursment
Multiple sclerosis
2145.3
115.3
93
*
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
110.7
88
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
1376.5
99.3
83
*
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
1014.4
87.4
75
*
H46
ICD-10 Finland
Optic neuritis
+∞
83.7
70
*
L03AB07
ATC
interferon beta-1a; parenteral
845.4
55.3
50
*
L03AX13
ATC
glatiramer acetate; parenteral
299.8
41.8
40
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
31.5
41.7
57
34
N86
ICPC
Multiple sclerosis
541.7
39.5
37
*
164
Kela drug reimbursment
Fingolimod
519.8
38.4
36
*
353
Kela drug reimbursment
Cladribine and fingolimod
457.4
34.9
33
*
XCK00
NOMESCO Finland
Perimetry
30.9
33.5
45
23
L04AA27
ATC
fingolimod; oral
381.2
30.3
29
*
TAB00
NOMESCO Finland
Lumbar puncture
25.7
28.3
40
23
L03AB08
ATC
interferon beta-1b; parenteral
347.0
28.0
27
*
L04AX07
ATC
dimethyl fumarate; oral
330.6
26.9
26
*
H48.1
ICD-10 Finland
Retrobulbar neuritis in diseases classified elsewhere
+∞
26.0
24
*
2AB04
NOMESCO Finland
NA
314.4
25.8
25
*
N04BB01
ATC
amantadine; oral
72.7
25.3
28
5
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
44.1
24.8
30
9
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
99.5
22.6
24
*
L04AA31
ATC
teriflunomide; oral
+∞
21.5
20
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
9.3
21.0
49
84
XCD10
NOMESCO Finland
Electrophysiological examination of eye
56.6
20.0
23
5
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
47.1
19.4
23
6
XKD06
NOMESCO Finland
Physiologic investigation of micturition
53.6
19.0
22
5
ZX120
NOMESCO Finland
Intravenous
9.9
18.6
40
58
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
18.2
17
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
11.3
17.0
33
39
N07XX09
ATC
[U] dimethyl fumarate; oral
+∞
16.0
15
*
M03BX01
ATC
baclofen; systemic
24.2
15.8
22
11
XKD00
NOMESCO Finland
Uroflowmetry
9.5
14.1
30
41
XA800
NOMESCO Finland
Neuropsychological investigation
14.1
14.1
24
21
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
16.8
13.4
21
15
4AA23
NOMESCO Finland
NA
+∞
12.7
12
*
H48.1*A69.2
ICD-10 Finland
Retrobulbar neuritis in Lyme disease
+∞
12.7
12
*
H02AB04
ATC
methylprednisolone; systemic
5.8
12.7
40
96
XCW99
NOMESCO Finland
Other investigative procedure of eye
7.3
12.3
31
55
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
9.3
11.9
25
33
N03AE01
ATC
clonazepam; systemic
10.6
11.4
22
25
G04BD04
ATC
oxybutynin; oral, transdermal
13.1
10.5
18
16
G04BD12
ATC
mirabegron; oral
8.5
10.1
22
31
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
28.9
10.1
13
5
R35
ICD-10 Finland
Polyuria
12.2
9.7
17
16
G04BD09
ATC
trospium; oral
24.1
9.6
13
6
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
9.5
9
*
H53.9
ICD-10 Finland
Visual disturbance, unspecified
13.0
8.9
15
13
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
22.0
8.7
12
6
R4110
NOMESCO Finland
Physiotherapy
3.7
8.6
45
170
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
96.7
8.5
9
*
H47.2
ICD-10 Finland
Optic atrophy
+∞
8.4
8
*
N06BA07
ATC
modafinil; oral
+∞
8.4
8
*
R4150
NOMESCO Finland
Neuropsychological rehabilitation
+∞
8.4
8
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
8.3
8.3
18
25
UKC02
NOMESCO Finland
Cystoscopy
5.6
7.9
23
49
N28
ICPC
Limited function/disability (N)
48.3
7.8
9
*
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
85.3
7.5
8
*
R1250
NOMESCO Finland
Evaluation of functional capability
17.1
7.4
11
7
L04AA40
ATC
cladribine; oral
+∞
7.4
7
*
L04AX01
ATC
azathioprine; systemic
6.7
7.3
18
31
H53.1
ICD-10 Finland
Subjective visual disturbances
6.7
6.9
17
29
XF400
NOMESCO Finland
ECG with 12 standard connections
4.3
6.9
26
73
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.0
6.9
22
52
N05CF01
ATC
zopiclone; oral
3.1
6.9
46
204
J01EA01
ATC
trimethoprim; systemic
3.2
6.9
43
182
N99
ICPC
Neurological disease other
42.6
6.8
8
*
N29
ICPC
Neurological sympt/complt other
24.1
6.8
9
*
A02BC02
ATC
pantoprazole; systemic
2.9
6.7
85
556
ZXA10
NOMESCO Finland
Bilateral
3.7
6.7
31
105
TKC20
NOMESCO Finland
Catheterisation of bladder
6.7
6.6
16
27
G04BD07
ATC
tolterodine; oral
12.0
6.4
11
10
N39.4
ICD-10 Finland
Other specified urinary incontinence
5.6
6.4
18
37
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
28.4
6.3
8
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.4
6.3
33
121
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
13.5
6.2
10
8
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
4.5
6.1
21
54
L28
ICPC
Limited function/disability (L)
4.7
6.1
20
49
G04BD08
ATC
solifenacin; oral
7.1
6.1
14
22
N03AX12
ATC
gabapentin; oral
3.5
6.0
29
101

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
34
18
25.03
44.62
1.2
1.3
—
—
—
0
0
101
354
8.70
30.48
15.3
5.2
—
—
—
0
0
121
550
14.30
26.75
19.0
5.7
0.5
0.5
e9/l
0.70
113
494
120
554
12.93
25.64
19.1
5.7
0.0
0.0
e9/l
2.91
112
496
79
249
6.35
25.60
10.5
2.4
0.2
0.3
e6/l
0.63
68
178
121
577
13.16
24.55
19.0
5.6
1.5
2.0
e9/l
5.00
114
525
120
573
12.19
24.11
19.6
6.1
0.2
0.2
e9/l
0.76
112
522
114
519
9.38
24.02
18.5
6.0
9.0
8.0
%
3.30
114
491
79
261
5.99
23.91
10.5
2.4
—
—
—
0
0
113
517
8.88
23.45
18.5
5.8
2.9
2.7
%
0.55
113
484
111
504
8.27
23.07
18.9
5.7
0.7
0.7
%
0.21
111
470
80
278
5.71
22.52
10.7
2.8
10.9
255.5
e6/l
0.53
69
210
24
23
12.51
22.45
1.0
1.7
—
—
—
0
0
114
539
8.81
22.40
18.5
5.8
24.7
29.6
%
5.48
114
510
20
15
15.52
21.57
1.0
1.6
—
—
—
0
0
89
354
5.58
20.87
12.4
3.3
17.5
114.6
e6/l
0.61
71
227
71
236
5.31
20.73
6.1
3.1
—
—
—
0
0
120
646
9.77
18.96
21.4
9.5
3.5
4.0
e9/l
2.37
112
577
99
478
5.19
16.98
20.7
8.4
0.0
0.0
e9/l
0.68
86
394
23
32
8.48
16.23
1.0
1.3
8.0
2.4
e6/l
1.53
15
25
15
11
15.24
16.18
1.0
1.3
—
—
—
0
0
20
24
9.63
15.81
1.4
1.3
—
—
—
0
0
70
278
4.20
15.22
16.6
7.1
—
—
—
0
0
89
420
4.38
15.13
5.8
2.9
—
—
—
0
0
18
5
41.21
14.87
1.0
1.0
—
—
—
0
0
67
288
3.67
12.42
7.9
2.3
—
—
—
0
0
37
107
4.41
12.05
1.7
1.4
—
—
—
0
0
49
179
3.75
11.48
1.6
1.6
—
—
—
0
0
92
516
3.54
10.64
9.9
4.6
0.0
0.0
estimate
—
9
105
92
524
3.45
10.21
6.8
3.2
0.0
0.0
estimate
—
9
104
23
53
5.04
9.78
1.5
1.2
—
—
—
0
0
91
524
3.33
9.73
6.7
3.3
0.0
0.0
estimate
—
9
99
111
768
3.69
7.87
11.1
3.9
—
—
—
0
0
10
7
15.30
6.51
1.1
1.0
1753.4
1850.4
miu/ml
—
10
7
12
22
5.90
6.41
2.9
3.1
—
—
—
0
0
133
1191
+∞
5.87
22.2
9.0
26.4
25.3
u/l
0.37
133
1158
43
210
2.55
5.56
6.5
3.9
—
—
—
0
0
122
978
3.99
5.22
31.5
13.4
13.5
13.6
%
0.20
122
969
48
256
2.37
5.07
6.0
3.9
7.4
7.4
ph
—
6
47
51
296
2.17
4.30
1.8
1.7
—
—
—
0
0
14
42
3.61
4.17
5.0
1.9
—
—
—
0
0
57
360
2.02
3.74
1.8
2.0
—
—
—
0
0
15
53
3.06
3.49
25.5
4.5
—
—
—
0
0
59
395
1.89
3.15
11.7
5.3
1.2
1.2
mmol/l
0.52
59
361
11
34
3.44
3.13
7.5
8.4
95.3
95.5
%
0.09
11
34
55
365
1.86
2.98
2.0
1.8
90.9
94.9
pmol/l
0.35
30
199
16
65
2.66
2.92
7.4
3.1
—
—
—
0
0
6
183
0.30
2.80
1.0
1.3
—
—
—
0
0
43
270
1.88
2.74
2.5
1.4
2.0
2.3
g/l
0.67
30
170
12
44
2.90
2.62
4.3
1.5
22.2
20.5
s
0.43
12
35
6
11
5.65
2.57
6.5
2.1
—
—
—
0
0
5
155
0.30
2.49
1.4
2.0
—
—
—
0
0
28
451
0.52
2.45
2.6
2.3
—
—
—
0
0
6
12
5.18
2.43
2.0
2.3
—
—
—
0
0
45
299
1.76
2.34
11.3
5.3
1.1
1.1
inr
—
8
96
27
156
1.92
2.17
3.2
2.5
68.1
202.4
ng/l
0.50
15
86
84
676
1.66
2.06
3.3
3.0
—
—
—
0
0
6
16
3.87
1.96
1.3
1.0
—
—
—
0
0
121
1092
2.20
1.87
22.2
10.7
139.5
139.7
mmol/l
0.24
121
1058
41
286
1.63
1.73
10.7
4.8
—
—
—
0
0
11
49
2.36
1.68
1.0
1.4
—
—
—
0
0
6
19
3.26
1.68
1.0
1.3
—
—
—
0
0
8
32
2.59
1.62
1.3
1.2
—
—
—
0
0
5
15
3.42
1.53
4.6
2.2
—
—
—
0
0
7
27
2.68
1.53
1.0
1.4
—
—
—
0
0
7
27
2.68
1.53
1.1
1.6
70.3
33.6
nmol/l
—
7
27
14
245
0.52
1.51
1.3
1.7
—
—
—
0
0
6
22
2.81
1.45
1.2
1.2
—
—
—
0
0
10
46
2.27
1.44
1.2
1.2
—
—
—
0
0
5
117
0.41
1.33
1.6
1.3
—
—
—
0
0
36
259
1.53
1.31
7.2
2.8
7.5
8.0
mmol/l
0.25
31
221
27
382
0.63
1.30
1.1
1.6
—
—
—
0
0
9
44
2.12
1.29
1.4
1.4
—
—
—
0
0
5
18
2.84
1.29
4.4
4.9
56.8
58.3
%
—
5
18
5
18
2.84
1.29
4.4
4.6
4.1
4.0
e9/l
—
5
18
26
174
1.61
1.28
1.3
1.4
373.3
415.1
titre
—
6
37
42
314
1.49
1.28
2.2
2.4
51.3
56.2
u/l
0.79
42
294
12
63
1.99
1.27
6.8
6.5
96.8
96.7
%
0.07
12
58
6
25
2.46
1.26
1.7
1.6
—
—
—
0
0
11
196
0.52
1.25
1.3
1.5
—
—
—
0
0
127
1203
2.23
1.24
12.6
10.1
—
—
—
0
0
13
72
1.89
1.20
6.5
6.1
13.4
12.7
kpa
0.19
13
67
13
72
1.89
1.20
6.5
6.1
4.9
5.1
kpa
0.19
13
67
35
256
1.50
1.18
2.6
1.7
0.6
0.8
mg/l
1.00
25
192
11
58
1.98
1.16
26.9
3.0
1.6
2.4
mmol/l
0.41
11
42
11
59
1.94
1.11
26.9
3.0
6.1
5.7
kpa
0.54
11
59
102
1101
0.68
0.99
3.6
3.6
4.8
4.8
mmol/l
0.15
96
1035
113
1045
1.54
0.98
6.2
4.8
1.9
1.7
mu/l
0.53
107
979
11
63
1.81
0.93
27.8
2.8
—
—
—
0
0
8
42
1.96
0.90
1.0
1.8
0.3
0.2
g/l
—
8
42
17
246
0.65
0.89
1.2
1.3
1.3
7.2
u/ml
—
6
98
102
1096
0.70
0.89
3.5
3.6
1.5
1.5
mmol/l
0.02
95
1029
13
82
1.65
0.81
7.8
4.3
0.7
0.6
%
—
6
24
11
66
1.73
0.81
1.1
1.5
—
—
—
0
0
0
24
0.00
0.80
0.0
1.1
—
—
—
0
0
12
75
1.66
0.78
8.4
4.6
0.0
0.0
%
—
5
21
9
56
1.65
0.74
1.2
1.8
—
—
—
0
0
7
39
1.84
0.74
1.0
1.6
—
—
—
0
0
13
85
1.59
0.72
22.9
18.2
—
1.3
—
0
19
116
1095
1.46
0.72
33.8
11.3
39.0
40.5
%
1.01
102
914
27
207
1.38
0.71
9.0
3.1
94.8
107.9
mg/l
0.09
20
128
5
27
1.88
0.69
2.0
1.9
—
—
—
0
0
36
292
1.32
0.67
1.3
1.3
0.6
1.5
u/ml
—
8
86
6
101
0.58
0.65
1.0
1.8
—
—
—
0
0
8
50
1.64
0.62
36.3
2.4
5.5
4.8
kpa
—
8
50
0
22
0.00
0.60
0.0
1.0
—
—
—
0
0
0
22
0.00
0.60
0.0
5.0
—
29.0
—
0
14
0
23
0.00
0.59
0.0
1.3
—
—
—
0
0
6
35
1.75
0.58
47.3
2.3
0.7
0.6
%
—
6
35
6
36
1.70
0.57
47.3
2.3
1.4
1.1
%
—
6
36
32
262
1.29
0.55
9.6
3.6
0.0
0.0
estimate
—
9
104
6
96
0.61
0.54
1.5
1.3
38.0
22.0
iu/l
—
6
81
11
75
1.51
0.52
1.0
1.2
—
—
—
0
0
15
111
1.40
0.49
1.7
1.2
93.4
156.4
iu/ml
—
8
45
5
83
0.59
0.47
1.8
1.4
—
—
—
0
0
53
469
1.22
0.47
2.1
2.0
—
—
—
0
0
11
77
1.47
0.47
1.1
1.5
—
—
—
0
0
13
173
0.72
0.45
1.5
1.6
332.0
459.5
pmol/l
2.69
13
153
100
1050
0.81
0.43
3.1
3.3
1.2
1.2
mmol/l
0.76
92
977
27
224
1.26
0.43
9.7
3.7
13.0
14.8
mg/mmol
0.10
21
134
32
273
1.23
0.40
1.5
1.6
1.4
1.3
mmol/l
0.22
27
243
100
1047
0.82
0.39
3.6
3.7
5.7
5.7
mmol/l
0.17
94
978
6
43
1.41
0.35
47.7
3.3
136.7
134.5
g/l
—
6
43
11
82
1.37
0.35
1.1
1.5
—
—
—
0
0
6
44
1.38
0.35
1.2
1.1
—
—
—
0
0
6
89
0.66
0.34
4.8
5.1
—
—
—
0
0
15
119
1.29
0.33
3.5
1.5
—
—
—
0
0
11
83
1.35
0.33
1.1
1.5
—
—
—
0
0
11
83
1.35
0.33
1.1
1.5
—
—
—
0
0
11
84
1.34
0.31
1.1
1.5
—
—
—
0
0
8
62
1.31
0.28
1.8
2.1
—
—
—
0
0
16
132
1.24
0.27
1.7
2.2
—
—
—
0
0
5
40
1.26
0.22
2.2
5.8
—
—
—
0
0
108
1109
0.86
0.22
4.0
3.9
2.9
2.9
mmol/l
0.05
99
1042
5
42
1.20
0.21
3.0
2.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
8.8
—
0.7
—
0
10
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
10
80
1.27
0.21
3.3
3.0
1.4
1.9
%
—
10
74
12
144
0.82
0.21
1.4
1.2
—
—
—
0
0
9
112
0.79
0.21
1.4
1.3
—
—
—
0
0
9
113
0.78
0.21
1.1
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
13.9
—
1062.1
—
0
14
0
14
0.00
0.20
0.0
15.8
—
1901.9
—
0
14
8
70
1.15
0.16
2.8
1.6
733.3
316.8
mu/l
—
8
62
6
78
0.76
0.16
1.0
1.3
1078.9
446.1
u/ml
—
6
68
9
109
0.81
0.13
1.7
1.4
—
—
—
0
0
15
135
1.13
0.10
2.0
1.3
—
—
—
0
0
6
53
1.14
0.09
6.3
3.2
6.2
4.9
kpa
—
6
48
35
333
1.07
0.08
2.5
2.0
—
—
—
0
0
6
73
0.81
0.08
1.5
1.2
—
—
—
0
0
13
118
1.11
0.07
3.5
3.8
1.4
1.7
ug/l
0.51
13
109
29
304
0.94
0.06
6.0
2.9
—
—
—
0
0
12
110
1.10
0.05
2.3
2.0
331.9
371.3
nmol/l
0.26
12
100
13
138
0.94
0.02
1.7
1.2
—
—
—
0
0
26
252
1.04
0.02
2.8
3.3
—
—
—
0
0
32
315
1.02
0.00
3.2
2.9
19.9
20.0
ng/l
0.01
14
161
25
248
1.01
0.00
1.3
1.3
9.6
31.7
iu/ml
—
7
74
0
9
0.00
0.00
0.0
1.9
—
18.9
—
0
9
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
470.5
—
0
6
0
8
0.00
0.00
0.0
1.6
—
34.4
—
0
8
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
3.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
9
91
0.99
0.00
9.9
3.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
3.0
—
—
—
0
0
9
94
0.95
0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
27.0
—
0
5
0
5
0.00
0.00
0.0
1.0
—
161.4
—
0
5
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
6
68
0.88
0.00
3.0
2.6
34.7
25.7
u/ml
—
6
62
0
5
0.00
0.00
0.0
4.0
—
49.1
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
7.6
—
0
5
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint H7_RETROBULBNEURINOTH and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have H7_RETROBULBNEURINOTH.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: H7_RETROBULBNEURINOTH – Retrobulbar neuritis in diseases classified elsewhere

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data